SAFE Drugs Act of 2026
- Bill Number
- S. 3794
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-06-29T20:59:59Z
AI-Generated Summary
Purpose of the Legislation
The Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026 (SAFE Drugs Act of 2026) aims to strengthen oversight of compounded drugs—custom-made medications prepared by pharmacies or facilities—to prevent the production of unsafe, fraudulent, or experimental versions that mimic commercially available drugs. It seeks to protect public health by limiting excessive compounding of such copies and improving tracking and inspections.
Key Provisions
- Limits on Compounding Copies of Commercial Drugs: Pharmacies and physicians can compound drugs that are essentially copies of commercially available ones no more than 20 times per month. A "copy" is defined as a drug with the same active ingredient as a market-available product, without significant changes tailored to an individual patient's needs (as determined by the prescribing doctor). Commercially available drugs are those sold in the U.S. market from facilities meeting federal manufacturing standards and not listed as discontinued.
- Reporting Requirements: For 2025 and later, if a pharmacy, facility, or physician compounds more than 20 copies of commercial drugs per month for out-of-state patients, they must submit an annual report to the Secretary of Health and Human Services (who oversees the FDA). The report lists drug types and monthly compounding counts. Hospitals are exempt for in-house patient use. Reports are due by year-end in a format set by the FDA.
- Inspections for Large-Scale Outsourcing Facilities: Defines "large-scale" as facilities compounding any drug more than 100 times per year. These must undergo an FDA inspection before starting operations and reinspections at least every two years, as part of the existing risk-based inspection system.
- Registration and Reporting for Outsourcing Facilities: Removes an exemption, requiring all outsourcing facilities (registered entities that compound drugs for hospitals or clinics) to comply with standard FDA registration and listing rules.
- Fee Adjustments: Changes the base establishment fee for outsourcing facilities from a fixed $15,000 to an amount set by the FDA Secretary, based on needs to fund safety activities for compounded drugs.
- Delayed Implementation: Provisions on inspections, registration, and reporting for outsourcing facilities take effect 6 months after enactment.
Significant Changes to Existing Law
- Amends Section 503A of the FD&C Act (governing pharmacy compounding) to tighten the threshold for copying commercial drugs from broader allowances to a strict 20-times-per-month limit and adds precise definitions to prevent loopholes.
- Introduces a new reporting subsection (d) to Section 503A, requiring transparency for interstate compounding of copy drugs, which was not previously mandated.
- Adds inspection rules to Section 503B (outsourcing facilities) for high-volume operations and eliminates their prior exemption from routine registration under Section 510, increasing federal tracking.
- Replaces a fixed fee in Section 744K with a flexible one tied to safety funding, allowing the FDA to adapt costs dynamically.
Potential Impacts
- Government Agencies: The FDA gains enhanced tools for monitoring and inspecting, potentially increasing workload and costs but improving enforcement of drug safety. Fees could help fund these efforts without relying solely on general budgets.
- Citizens: Patients may benefit from safer compounded drugs, reducing risks from unapproved or poorly made copies, especially for those needing custom medications (e.g., due to allergies or shortages). However, stricter limits could reduce access to affordable compounded alternatives in some cases.
- International Relations: Minimal direct impact, as the bill focuses on U.S.-based compounding and commercial drugs sold domestically; it does not address imports or exports explicitly.
Main Stakeholders Affected
- Compounding Pharmacies and Outsourcing Facilities: Face new limits, reporting duties, and inspections, particularly larger operations, which could raise compliance costs and operational burdens.
- Physicians and Hospitals: Physicians prescribing compounded drugs must justify significant changes; hospitals are partially exempt from reporting but still subject to overall rules.
- Patients and Consumers: Primary beneficiaries through improved safety, but may see changes in availability of certain compounded options.
- FDA and Regulators: Empowered with more data and authority to oversee the industry, aiding in preventing contamination or fraud (e.g., referencing past issues like the 2012 fungal meningitis outbreak from compounded drugs).
- Drug Manufacturers: Indirectly protected, as limits on copies could reduce competition from cheaper compounded versions of their products.
Notable Legal, Constitutional, or Political Implications
- Legal: Bolsters FDA authority under the FD&C Act without creating new agencies, emphasizing interstate commerce oversight (a federal power). Definitions clarify ambiguities in prior compounding laws (e.g., from the 2013 Drug Quality and Security Act), potentially reducing litigation over what constitutes a "copy."
- Constitutional: Aligns with Congress's commerce clause powers to regulate drugs affecting public health across state lines; no apparent free speech or due process issues, as requirements are procedural and tied to safety.
- Political: Introduced by bipartisan senators (Banks and Heinrich), it reflects ongoing concerns post-scandals about compounded drug risks. Could face pushback from pharmacy lobbies over burdens on small businesses, but supports broader goals of drug safety amid rising scrutiny of supply chains. The flexible fee structure gives the executive branch discretion, which might invite future congressional oversight.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-02-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2026-02-05: Introduced in Senate
Bill Versions
- Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026 — issued 2026-02-05 — PDF (6 pages)